RUBY — Rubius Therapeutics Share News
0.000.00%
Last trade - 00:00Brief: Rubius Therapeutics Inc - Plan To File Investigational New Drug Application By End Of 2020."
Brief: Rubius Therapeutics To Present RTX-321 Preclinical Data At American Association Of Cancer Research Annual Meeting
Brief: Rubius Therapeutics Highlights Preclinical Data At The American Society Of Gene & Cell Therapy 23Rd Annual Meeting For Rtx-321, An Oncology Product Candidate For Hpv-Positive Cancers
Brief: Rubius Therapeutics Reports First Quarter 2020 Financial Results And Provides Operational Update
Brief: Rubius Therapeutics Announces Dosing Of First Patient In Cellular Therapy Trial For Treatment Of Solid Tumors
Rubius Therapeutics: Hits record low after co deprioritizes blood disorder drug
Brief: Rubius Therapeutics Q4 Loss Per Share $0.56
Brief: Rubius Therapeutics Appoints Christina Coughlin As Chief Medical Officer
Brief: Rubius Therapeutics Q3 Loss Per Share $0.59
U.S. RESEARCH ROUNDUP- Caseys General Stores, Five Below, Tiffany & Co
Brief: Rubius Therapeutics Reports Q2 Loss Per Share $0.50
Brief: Rubius Therapeutics Files For Mixed Shelf Of Upto $450 Mln
Upcoming CMS decisions to minimally impact current cancer CAR-T therapies - analyst
Brief: Rubius Therapeutics Inc - Torben Straight Nissen Notified Co Of His Resignation From Role of President
Brief: Rubius Therapeutics Reports Q1 Loss Per Share $0.42
Brief: Rubius Therapeutics Plans To File Investigational New Drug Application For Rtx-240 By Early 2020
Brief: Rubius Therapeutics Reports Q4 Loss Per Share Of $0.35
Brief: Rubius Therapeutics Announces FDA Clearance Of Investigational New Drug Application For Red Cell Therapeutic, RTX-134
Brief: Rubius Therapeutics Secures $75 Mln Loan Facility